Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy

Ischemic stroke is the most common type of stroke and thrombolytic therapy is the only approved treatment. However, current thrombolytic therapy with tissue plasminogen activator (tPA) is often hampered by the increased risk of hemorrhage. Plasmin, a direct fibrinolytic, has a significantly superior...

Descripción completa

Detalles Bibliográficos
Autores principales: Aamir, Ramsha, Fyffe, Cameron, Korin, Netanel, Lawrence, Daniel A., Su, Enming J., Kanapathipillai, Mathumai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584024/
https://www.ncbi.nlm.nih.gov/pubmed/34768908
http://dx.doi.org/10.3390/ijms222111477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584024/
https://www.ncbi.nlm.nih.gov/pubmed/34768908
http://dx.doi.org/10.3390/ijms222111477

Ejemplares similares